Structural & Congenital Heart Disease

The undertreatment of aortic stenosis in the U.S. is severe, driven by deep-rooted racial and sex disparities and a disconnect between patients and their clinicians.

An analysis of PARTNER 2 data, published in the June edition of the Journal of the American College of Cardiology, suggests transcatheter aortic valve replacement (TAVR) within failed bioprosthetic surgical aortic valves is a viable long-term solution for high-risk individuals, with patients seeing “excellent” functional and quality of life outcomes three years after the procedure.

Patients with end-stage renal disease (ESRD) face higher risks of in-hospital mortality and bleeding with transcatheter aortic valve replacement (TAVR) than patients who aren’t dialysis-dependent, researchers report in the Journal of the American College of Cardiology.

Results from the TRILUMINATE study, presented this week at EuroPCR 2019 in Paris, suggest Abbott’s minimally invasive tricuspid valve repair system is an effective solution for patients with structural heart disease, reducing the severity of tricuspid regurgitation (TR) in more than 85% of test cases.

As rates of infective endocarditis among intravenous drug users skyrocket, cardiologists are finding that treating the heart condition without addressing the disease of addiction contributes to readmissions and mortality. 

Clinical trials presented at ACC.19 flipped the script on TAVR vs. SAVR. 

The global market for transcatheter treatment of the mitral and aortic valves is expected to increase from $4 billion to $8 billion in the next five years, but barriers exist. 

Cardiac abnormalities stemming from preterm birth can be corrected with a three-and-a-half-month exercise program in patients’ teens and twenties, according to a drug-free trial of Canadian adults.

The addition of 2.4% hydrogen to hypoxia patients’ traditional ventilation gases improved neurologic outcomes and reduced tissue injury in a recent study of piglets, suggesting hydrogen might be a beneficial addition to therapy for babies undergoing surgery for congenital heart disease (CHD).

CMS saw an influx of public commentary after it first published a draft of recommendations for revising the United States’ national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) more than a month ago. Now that the 30-day comment period is over, the agency has a decision to make.

Boston Scientific’s LOTUS Edge Aortic Valve System was cleared by the FDA April 23 for use in high-risk surgical candidates with severe aortic stenosis.

Interventional cardiologists in Poland used 3D goggles to help them see inside a patient’s chest during percutaneous mitral balloon commissurotomy, a procedure to treat severe mitral stenosis.